Empagliflozin-d4

Empagliflozin-d4 is intended for use as an internal standard for the quantification of empagliflozin (Cay-17375) by GC- or LC-MS. Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC50 = 3.1 nM for the human transporter). It is selective for SGLT2 over SGLT1, -4, -5, and -6 (IC50s = 8.3, 11, 1.1, and 2 µM, respectively). Dietary administration of empagliflozin (0.03% for 10 weeks) reduces non-fasting blood glucose levels, as well as aortic superoxide levels and cardiac interstitial fibrosis, in db/db mice. It also decreases the severity of glomerulosclerosis, as well as reduces the escape latency in the Morris water maze, in the same model. Formulations containing empagliflozin have been used in the treatment of type 2 diabetes.Formal Name: (1S)-1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl-d4]methyl]phenyl]-D-glucitol. Molecular Formula: C23H23D4ClO7. Formula Weight: 454.9. Purity: >99% deuterated forms (d1-d4). Formulation: (Request formulation change), A solid. Solubility: DMSO: Solube. SMILES: ClC(C=CC([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)=C2)=C2CC3=C([2H])C([2H])=C(O[C@@H]4COCC4)C([2H])=C3[2H]. InChi Code: InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1/i1D,2D,4D,5D. InChi Key: OBWASQILIWPZMG-CPTKLOLCSA-N.